Close
Get it on Google Play

Genentech (DNA) Said Avastin Plus Interferon Therapy Improved Progression-Free Survival in RCC

December 12, 2006 7:15 AM EST Send to a Friend
Genentech, Inc. (NYSE: DNA) said interim analysis shows that a randomized Phase III clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login